R46-28795-15232
4 vaccinations
3 coded responses
38 check-ins
3 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 606 / IL
- Registered
- 2021-01-05
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-05
Registered in v-safe
-
2021-01-05
Dose 1 — Pfizer-BioNTech
- 2021-01-06
- 2021-01-07
- 2021-01-08
- 2021-01-09
- 2021-01-10
- 2021-01-12
- 2021-01-20
- 2021-01-26
-
2021-01-27
Dose 2 — Pfizer-BioNTech
- 2021-01-27
-
2021-01-28
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
-
2021-01-29
Survey response — days 1–6 daily, dose 2MedDRA: Lymphadenopathy — Feeling: Good · Site: Pain · Fatigue or tirednessFree text: Slightly swollen lymph nodes in the neckMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-30
- 2021-01-31
- 2021-02-01
- 2021-02-02
- 2021-02-03
- 2021-02-10
- 2021-02-17
- 2021-02-24
- 2021-03-03
- 2021-03-10
- 2021-04-28
- 2021-07-28
-
2022-01-13
Dose 3 — Pfizer-BioNTech
- 2022-01-14
- 2022-01-15
- 2022-01-16
- 2022-01-17
- 2022-01-19
- 2022-01-20
- 2022-01-29
- 2022-02-03
- 2022-02-10
-
2022-02-17
Survey response — day 35, dose 3MedDRA: Nasopharyngitis, Oropharyngeal pain, Respiratory tract congestion, Rhinorrhoea, SARS-CoV-2 test negative — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Common cold, confirmed with a respiratory panel. Tested negative for covid x2. Sore throat, congestion, runny noseMedDRA releases: 2024-11 · check-in free text available
- 2022-02-24
-
2022-04-14
Survey response — 3 months, dose 3MedDRA: COVID-19, Cough — Feeling: Good · Be unable to do your normal daily activitiesFree text: COVID positive in March 2022, still have a lingering dry cough but infrequent and getting better.MedDRA releases: 2024-11 · check-in free text available
- 2022-07-14
-
2022-07-22
Dose 4 — Pfizer-BioNTech
- 2022-10-21
- 2023-01-20
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-05 | Pfizer-BioNTech | |
| 2 | 2021-01-27 | Pfizer-BioNTech | |
| 3 | 2022-01-13 | Pfizer-BioNTech | No |
| 4 | 2022-07-22 | Pfizer-BioNTech | No |
Free text
Release 3 — days 1–6 daily, dose 2
Systemic reaction (other): Slightly swollen lymph nodes in the neck
Release 11 — day 35, dose 3
Symptoms: Common cold, confirmed with a respiratory panel. Tested negative for covid x2. Sore throat, congestion, runny nose
Release 11 — 3 months, dose 3
Symptoms: COVID positive in March 2022, still have a lingering dry cough but infrequent and getting better.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | SARS-CoV-2 test negative | · | · | ✓ |
| SRO | Lymphadenopathy | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release